Zacks Investment Research·1 day ago
Reasons Why Investors Should Consider Betting on Neurocrine StockNBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
Neurocrine Biosciences, Inc.(NBIX)Earnings, Financials & Key Ratios
NBIX•NASDAQ
$177.49
38.0× P/E·Price updated Jul 7, 2026
AboutNeurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.Show more
- Revenue$2.86B+21.4%
- EBITDA$649M+8.6%
- Net Income$479M+40.2%
- EPS (Diluted)4.67+41.9%
- Gross Margin98.18%-0.4%
- EBITDA Margin22.7%-10.6%
- Operating Margin21.64%-10.6%
- Net Margin16.73%+15.5%
- ROE16.38%+15.7%
NBIX Price & Volume
Neurocrine Biosciences, Inc. (NBIX) stock price & volume — 10-year historical chart
Loading chart...
Ingrezza Dominance Drives Robust Revenue Growth Trajectory
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Accelerating
Profitability:Moderate
Financial:Healthy
Cash Flow:Robust
Primary Risk:Single product revenue concentration
Key Thesis Takeaways
- Neurocrine Biosciences demonstrates a compelling growth profile anchored by the market penetration of Ingrezza, which fueled a 42.2% year-over-year revenue increase in 2026Q1.
- While the company maintains a fortress balance sheet with a 0.12 debt-to-equity ratio, investors should monitor the ongoing reliance on a single-product revenue stream and the impact of $57.2 million in quarterly stock-based compensation on GAAP earnings quality.
- The firm's ability to scale operating margins to 23.7% while funding an extensive R&D pipeline suggests a sustainable path toward long-term value creation.
Verdict Logic
the company's forward P/E of 21.83 appears attractive given the 42.2% revenue growth rate and the successful transition to positive retained earnings of $589.6 million.
NBIX Growth Metrics
Neurocrine Biosciences, Inc. (NBIX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years64.45%
5 Years22.29%
3 Years24.32%
TTM28.59%
Profit CAGR
10 Years-
5 Years3.28%
3 Years45.77%
TTM118.64%
EPS CAGR
10 Years-
5 Years2.34%
3 Years44.12%
TTM120%
Return on Capital
10 Years3.4%
5 Years13.62%
3 Years16.14%
Last Year17.44%
NBIX Recent Earnings
Neurocrine Biosciences, Inc. (NBIX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$1.94+59.0%
$1.22
Rev
$815M+6.0%
$768M
Q1 2026
Feb 11, 2026Metric
Actual
Est
EPS
$1.88+4.4%
$1.80
Rev
$806M+1.9%
$790M
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$2.04+29.1%
$1.58
Rev
$795M-1.5%
$807M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$1.06+8.2%
$0.98
Rev
$688M-7.9%
$746M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $1.94vs $1.22+59.0% | $815Mvs $768M+6.0% |
| Q1 2026 | Feb 11, 2026 | $1.88vs $1.80+4.4% | $806Mvs $790M+1.9% |
| Q4 2025 | Oct 28, 2025 | $2.04vs $1.58+29.1% | $795Mvs $807M-1.5% |
| Q3 2025 | Jul 30, 2025 | $1.06vs $0.98+8.2% | $688Mvs $746M-7.9% |
Based on last 12 quarters of dataView full earnings history →
Latest NBIX News
Recent stock market news and headlines for Neurocrine Biosciences, Inc. (NBIX)
Seeking Alpha·5 days ago
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For SolenoNeurocrine Biosciences, Inc. remains a Buy, driven by robust growth from Ingrezza, Crenessity, and the recent Vykat acquisition. Q1 2026 revenues rose 44% year-on-year to $811m, with Ingrezza and Crenessity annualizing at blockbuster levels and Vykat showing rapid ramp-up. NBIX stock valuation reflects high-growth expectations; forward P/S ~5.1x and P/E ~30x, justified by an expanding commercial portfolio and pipeline catalysts.
PRNewsWire·6 days ago
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal HyperplasiaSAN DIEGO, July 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH.
Zacks Investment Research·6 days ago
Neurocrine Biosciences (NBIX) Is Up 6.46% in One Week: What You Should KnowDoes Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research·6 days ago
5 Relative Price Strength Stocks to Buy for the Second HalfNBIX, MYRG, XYZ, DK and DY show strong relative price strength, upbeat estimate revisions and solid fundamentals heading into the second half.
Peers Comparison
Key metrics vs top competitors for Neurocrine Biosciences, Inc. (NBIX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $177.49 | $17.81B | 38.01 | 21.45% | 16.73% | 16.38% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Compare NBIX vs Peers
Neurocrine Biosciences, Inc. (NBIX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NBIX SEC Filings & Documents
Neurocrine Biosciences, Inc. (NBIX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Feb 11, 2026·SEC
10-K Annual Reports
210-Q Quarterly Reports
6Get notified when NBIX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NBIX Frequently Asked Questions
Neurocrine Biosciences, Inc. (NBIX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Neurocrine Biosciences, Inc.'s revenue?
Neurocrine Biosciences, Inc. (NBIX) reported $3.10B in revenue for fiscal year 2025. This represents a 16058% increase from $19.2M in 1996.
How fast is Neurocrine Biosciences, Inc. growing?
Neurocrine Biosciences, Inc. (NBIX) grew revenue by 21.4% over the past year. This is strong growth.
Is NBIX profitable?
Yes, Neurocrine Biosciences, Inc. (NBIX) is profitable, generating $668.6M in net income for fiscal year 2025 (16.7% net margin).
Dividend & Returns
What is NBIX's return on equity?
Neurocrine Biosciences, Inc. (NBIX) has a return on equity (ROE) of 16.4%. This is reasonable for most industries.
What is Neurocrine Biosciences, Inc.'s free cash flow?
Neurocrine Biosciences, Inc. (NBIX) generated $831.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.